Alejandro Balsa , Petra Díaz del Campo Fontecha , Lucía Silva Fernández , José Valencia Martín , Virginia Nistal Martínez , Fernando León Vázquez , M. Vanesa Hernández Hernández , Héctor Corominas , Rafael Cáliz Cáliz , José María Aguado García , Gloria Candelas Rodríguez , Nora Ibargoyen Roteta , Arturo Martí Carvajal , M. Nieves Plana Farras , Janet Puñal Riobóo , Hye Sang Park , Yolanda Triñanes Pego , Virginia Villaverde García
{"title":"关于类风湿关节炎患者靶向生物或合成FAME治疗风险管理的建议","authors":"Alejandro Balsa , Petra Díaz del Campo Fontecha , Lucía Silva Fernández , José Valencia Martín , Virginia Nistal Martínez , Fernando León Vázquez , M. Vanesa Hernández Hernández , Héctor Corominas , Rafael Cáliz Cáliz , José María Aguado García , Gloria Candelas Rodríguez , Nora Ibargoyen Roteta , Arturo Martí Carvajal , M. Nieves Plana Farras , Janet Puñal Riobóo , Hye Sang Park , Yolanda Triñanes Pego , Virginia Villaverde García","doi":"10.1016/j.reuma.2023.07.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To present recommendations based on the available evidence and the consensus of experts, for risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis.</p></div><div><h3>Methods</h3><p>Clinical research questions relevant to the purpose of the document were identified. These questions were reformulated in PICO format (patient, intervention, comparison, outcome) by a panel of experts, selected based on their experience in the area. A systematic review of the evidence was carried out, grading according to the GRADE criteria (Grading of Recommendations Assessment, Development, and Evaluation). Specific recommendations were then formulated.</p></div><div><h3>Results</h3><p>Six PICO questions were proposed by the panel of experts based on their clinical relevance and the existence of recent information regarding the risk of occurrence of serious infections, the risk of reactivation of the hepatitis<!--> <!-->B virus, the risk of reactivation of the virus varicella-zoster, the risk of appearance of skin (melanoma and non-melanoma) or hematological cancer, the risk of appearance of thromboembolic disease and the risk of progression of the human papilloma virus.</p><p>A total of 29 recommendations were formulated, structured by question, based on the evidence found and the consensus of the experts.</p></div><div><h3>Conclusions</h3><p>The SER recommendations on risk management of treatment with biologic therapies and JAK inhibitors in rheumatoid arthritis are presented.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"19 10","pages":"Pages 533-548"},"PeriodicalIF":1.2000,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recomendaciones SER sobre la gestión de riesgo del tratamiento con FAME biológicos o sintéticos dirigidos en pacientes con artritis reumatoide\",\"authors\":\"Alejandro Balsa , Petra Díaz del Campo Fontecha , Lucía Silva Fernández , José Valencia Martín , Virginia Nistal Martínez , Fernando León Vázquez , M. Vanesa Hernández Hernández , Héctor Corominas , Rafael Cáliz Cáliz , José María Aguado García , Gloria Candelas Rodríguez , Nora Ibargoyen Roteta , Arturo Martí Carvajal , M. Nieves Plana Farras , Janet Puñal Riobóo , Hye Sang Park , Yolanda Triñanes Pego , Virginia Villaverde García\",\"doi\":\"10.1016/j.reuma.2023.07.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To present recommendations based on the available evidence and the consensus of experts, for risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis.</p></div><div><h3>Methods</h3><p>Clinical research questions relevant to the purpose of the document were identified. These questions were reformulated in PICO format (patient, intervention, comparison, outcome) by a panel of experts, selected based on their experience in the area. A systematic review of the evidence was carried out, grading according to the GRADE criteria (Grading of Recommendations Assessment, Development, and Evaluation). Specific recommendations were then formulated.</p></div><div><h3>Results</h3><p>Six PICO questions were proposed by the panel of experts based on their clinical relevance and the existence of recent information regarding the risk of occurrence of serious infections, the risk of reactivation of the hepatitis<!--> <!-->B virus, the risk of reactivation of the virus varicella-zoster, the risk of appearance of skin (melanoma and non-melanoma) or hematological cancer, the risk of appearance of thromboembolic disease and the risk of progression of the human papilloma virus.</p><p>A total of 29 recommendations were formulated, structured by question, based on the evidence found and the consensus of the experts.</p></div><div><h3>Conclusions</h3><p>The SER recommendations on risk management of treatment with biologic therapies and JAK inhibitors in rheumatoid arthritis are presented.</p></div>\",\"PeriodicalId\":47115,\"journal\":{\"name\":\"Reumatologia Clinica\",\"volume\":\"19 10\",\"pages\":\"Pages 533-548\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2023-10-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reumatologia Clinica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1699258X23001729\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia Clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699258X23001729","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Recomendaciones SER sobre la gestión de riesgo del tratamiento con FAME biológicos o sintéticos dirigidos en pacientes con artritis reumatoide
Objective
To present recommendations based on the available evidence and the consensus of experts, for risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis.
Methods
Clinical research questions relevant to the purpose of the document were identified. These questions were reformulated in PICO format (patient, intervention, comparison, outcome) by a panel of experts, selected based on their experience in the area. A systematic review of the evidence was carried out, grading according to the GRADE criteria (Grading of Recommendations Assessment, Development, and Evaluation). Specific recommendations were then formulated.
Results
Six PICO questions were proposed by the panel of experts based on their clinical relevance and the existence of recent information regarding the risk of occurrence of serious infections, the risk of reactivation of the hepatitis B virus, the risk of reactivation of the virus varicella-zoster, the risk of appearance of skin (melanoma and non-melanoma) or hematological cancer, the risk of appearance of thromboembolic disease and the risk of progression of the human papilloma virus.
A total of 29 recommendations were formulated, structured by question, based on the evidence found and the consensus of the experts.
Conclusions
The SER recommendations on risk management of treatment with biologic therapies and JAK inhibitors in rheumatoid arthritis are presented.
期刊介绍：
Una gran revista para cubrir eficazmente las necesidades de conocimientos en una patología de etiología, expresividad clínica y tratamiento tan amplios. Además es La Publicación Oficial de la Sociedad Española de Reumatología y del Colegio Mexicano de Reumatología y está incluida en los más prestigiosos índices de referencia en medicina.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
